Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|19|7|938-944

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.19, Iss.7, 2012-03, pp. : 938-944

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sorafenib (BAY 43-9006): Review of Clinical Development

By  

Current Clinical Pharmacology, Vol. 1, Iss. 3, 2006-01 ,pp. : 223-228

Bentham Science Publishers

Access to resources Recommend Favorite

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma

By Guan Yong-Song   He Qing  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 2, 2011-02 ,pp. : 303-313

Informa Healthcare

Access to resources Recommend Favorite

Selection of Patients with Hepatocellular Carcinoma for Sorafenib

By Abou-Alfa Ghassan K.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 4, 2009-04 ,pp. : 397-403

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

BAY 43-9006: Early Clinical Data in Patients with Advanced Solid Malignancies

By  

Current Pharmaceutical Design, Vol. 8, Iss. 25, 2002-11 ,pp. : 2249-2253

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Application of Sorafenib for Treating Hepatocellular Carcinoma and Beyond

By  

Clinical Cancer Drugs, Vol. 2, Iss. 2, 2015-10 ,pp. : 128-137

Bentham Science Publishers

Access to resources Recommend Favorite